Cargando…

Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy

Androgen deprivation therapy, primarily via a gonadotropin-releasing hormone receptor agonist or antagonist together with or without an androgen receptor antagonist, remains the mainstay of medical treatment for advanced prostate cancer. Meanwhile, relugolix has been developed as the first orally ac...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tatenuma, Tomoyuki, Miyamoto, Hiroshi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10408655/ https://www.ncbi.nlm.nih.gov/pubmed/37559910 http://dx.doi.org/10.2147/DDDT.S373546

Ejemplares similares

Relugolix: A Review in Advanced Prostate Cancer
por: Shirley, Matt
Publicado: (2023)

Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer
por: Saad, Fred, et al.
Publicado: (2021)

Correction to: Relugolix: A Review in Advanced Prostate Cancer
por: Shirley, Matt
Publicado: (2023)

Relugolix – The novel oral androgen deprivation therapy for prostate cancer
por: Jena, Rahul
Publicado: (2020)

A Phase I Clinical Trial Evaluating the Safety and Dosing of Relugolix with Novel Hormonal Therapy for the Treatment of Advanced Prostate Cancer
por: De La Cerda, Jose, et al.
Publicado: (2023)

A Randomized Open-Label Study of Relugolix Alone or Relugolix Combination Therapy in Premenopausal Women
por: Lukes, Andrea, et al.
Publicado: (2023)

Relugolix: A new kid on the block among gonadotrophin-releasing hormone antagonists
por: Fragkoulis, Charalampos, et al.
Publicado: (2021)

Long-term Relugolix Combination Therapy for Symptomatic Uterine Leiomyomas
por: Al-Hendy, Ayman, et al.
Publicado: (2022)

Coadministration of Apalutamide and Relugolix in Patients with Localized Prostate Cancer at High Risk for Metastases
por: Brown, Gordon, et al.
Publicado: (2022)

Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer
por: Shore, Neal D., et al.
Publicado: (2023)

Relugolix as a promising novel oral GnRH antagonist for prostate cancer treatment
por: Lv, Jialu, et al.
Publicado: (2020)

A case of lichenoid drug eruption associated with relugolix
por: Han, Joseph, et al.
Publicado: (2023)

A case of adenomyosis with leiomyoma that was effectively treated with relugolix and kamishoyosan add-on therapy
por: Sasamori, Yukifumi, et al.
Publicado: (2021)

A Practical Guide to Relugolix: Early Experience With Oral Androgen Deprivation Therapy
por: Kasparian, Saro, et al.
Publicado: (2023)

Preference for enzalutamide capsules versus tablet pills in patients with prostate cancer
por: Ninomiya, Sahoko, et al.
Publicado: (2019)

Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy
por: Romigi, Andrea, et al.
Publicado: (2018)

Development of relugolix combination therapy as a medical treatment option for women with uterine fibroids or endometriosis
por: Arjona Ferreira, Juan C., et al.
Publicado: (2022)

Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate Cancer
por: Saad, Fred, et al.
Publicado: (2023)

Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer
por: Gallagher, Lindsey, et al.
Publicado: (2023)

Uterine Fibroids: A Podcast on Patient and Physician Perspectives on Medical Management and a New Medical Therapy (Relugolix Combination Therapy)
por: Venable, Sateria R., et al.
Publicado: (2023)

Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial
por: Hoshiai, Hiroshi, et al.
Publicado: (2021)

Recent Advances in the Management of Hormone-Sensitive Oligometastatic Prostate Cancer
por: Marvaso, Giulia, et al.
Publicado: (2022)

Population PK and Semimechanistic PK/PD Modeling and Simulation of Relugolix Effects on Testosterone Suppression in Men with Prostate Cancer
por: Lee, Tien‐Yi, et al.
Publicado: (2022)

The novel oral gonadotropin‐releasing hormone receptor antagonist relugolix is a new option for controlled ovarian stimulation cycles
por: Komiya, Shinnosuke, et al.
Publicado: (2022)

A plain language summary of the long-term relugolix combination therapy study for uterine fibroids
por: Al-Hendy, Ayman, et al.
Publicado: (2023)

Profile of semaglutide in the management of type 2 diabetes: design, development, and place in therapy
por: Gomez-Peralta, Fernando, et al.
Publicado: (2019)

Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Has the Same Effect as Gonadotropin-Releasing Hormone Agonist Injections in Terms of Preparation for Transcervical Resection Myomectomy
por: Ito, Mika, et al.
Publicado: (2022)

Therapeutic effects of an oral gonadotropin‐releasing hormone receptor antagonist, relugolix, on preventing premature ovulation in mild ovarian stimulation for IVF
por: Nakao, Kazuki, et al.
Publicado: (2021)

Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids
por: Syed, Yahiya Y.
Publicado: (2022)

Characteristics of submucosal leiomyomas that could cause severe hemorrhage with relugolix: an observational study
por: Wada, Yoshimitsu, et al.
Publicado: (2023)

An Efficient UPLC-MS/MS Method Established to Detect Relugolix Concentration in Rat Plasma
por: Xing, Liying, et al.
Publicado: (2022)

Correction: Relugolix/Estradiol/Norethisterone (Norethindrone) Acetate: A Review in Symptomatic Uterine Fibroids
por: Syed, Yahiya Y.
Publicado: (2022)

Redefining Hormone Sensitive Disease in Advanced Prostate Cancer
por: Hou, Xiaoyu, et al.
Publicado: (2012)

Advancements in the treatment of metastatic hormone-sensitive prostate cancer
por: Li, Hengping, et al.
Publicado: (2022)

Profile of asfotase alfa in the treatment of hypophosphatasia: design, development, and place in therapy
por: Bowden, Sasigarn A, et al.
Publicado: (2018)

Profile of Linzagolix in the Management of Endometriosis, Including Design, Development and Potential Place in Therapy: A Narrative Review
por: Donnez, Jacques, et al.
Publicado: (2023)

Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results
por: Osuga, Yutaka, et al.
Publicado: (2021)

Spotlight on perampanel in the management of seizures: design, development and an update on place in therapy
por: Faulkner, Michele A
Publicado: (2017)

GABBR2 as a Downstream Effector of the Androgen Receptor Induces Cisplatin Resistance in Bladder Cancer
por: Elahi Najafi, Mohammad Amin, et al.
Publicado: (2023)

Profile of plecanatide in the treatment of chronic idiopathic constipation: design, development, and place in therapy
por: Sharma, Amol, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ao5v6qmtmqal9h1sq1ejde2sns